Patient characteristics
| Data cutoff 1 August 2019 . | N = 22 . |
|---|---|
| Median age (range), y | 63 (42-83) |
| Median time since initial diagnosis (range), mo | 48 (8-184) |
| Median no. of organ systems involved, n (%) | 2 (1-5) |
| Cardiac biomarker stage II or III disease, n (%) | 20 (91) |
| NYHA class II or III, n (%) | 11 (50) |
| Median NTproBNP (range), pg/mL | 1264 (32-3962) |
| Median troponin I (range), ng/mL | 0.0345 (<0.006-0.292) |
| Median urine protein excretion (range), g/24 h | 0.53 (0-10.1) |
| Median eGFR (range), mL/min/1.73 m2 | 58 (20-112) |
| Renal stage II or III disease, n (%) | 11 (50) |
| Median no. of BM plasmacytosis (range), % | 10 (5-20) |
| Median time since last plasma cell–directed treatment (range), mo | 9 (1-180) |
| Median no. of prior therapies (range) | 2 (1-7) |
| High-dose melphalan/SCT, n (%) | 15 (68) |
| Proteasome inhibitor, n (%) | 16 (73) |
| Immunomodulatory agent, n (%) | 9 (41) |
| Median dFLC (range), mg/L | 80.7 (2.9-854) |
| Data cutoff 1 August 2019 . | N = 22 . |
|---|---|
| Median age (range), y | 63 (42-83) |
| Median time since initial diagnosis (range), mo | 48 (8-184) |
| Median no. of organ systems involved, n (%) | 2 (1-5) |
| Cardiac biomarker stage II or III disease, n (%) | 20 (91) |
| NYHA class II or III, n (%) | 11 (50) |
| Median NTproBNP (range), pg/mL | 1264 (32-3962) |
| Median troponin I (range), ng/mL | 0.0345 (<0.006-0.292) |
| Median urine protein excretion (range), g/24 h | 0.53 (0-10.1) |
| Median eGFR (range), mL/min/1.73 m2 | 58 (20-112) |
| Renal stage II or III disease, n (%) | 11 (50) |
| Median no. of BM plasmacytosis (range), % | 10 (5-20) |
| Median time since last plasma cell–directed treatment (range), mo | 9 (1-180) |
| Median no. of prior therapies (range) | 2 (1-7) |
| High-dose melphalan/SCT, n (%) | 15 (68) |
| Proteasome inhibitor, n (%) | 16 (73) |
| Immunomodulatory agent, n (%) | 9 (41) |
| Median dFLC (range), mg/L | 80.7 (2.9-854) |
BM, bone marrow; NYHA, New York Heart Association; SCT, stem cell transplantation.